ANI Pharmaceuticals, Inc.

BST:BSFA Stock Report

Market Cap: €1.0b

ANI Pharmaceuticals Management

Management criteria checks 3/4

ANI Pharmaceuticals' CEO is Nikhil Lalwani, appointed in Sep 2020, has a tenure of 4.17 years. total yearly compensation is $8.08M, comprised of 9.5% salary and 90.5% bonuses, including company stock and options. directly owns 1.92% of the company’s shares, worth €20.08M. The average tenure of the management team and the board of directors is 3 years and 4.2 years respectively.

Key information

Nikhil Lalwani

Chief executive officer

US$8.1m

Total compensation

CEO salary percentage9.5%
CEO tenure4.2yrs
CEO ownership1.9%
Management average tenure3yrs
Board average tenure4.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Nikhil Lalwani's remuneration changed compared to ANI Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

US$23m

Mar 31 2024n/an/a

US$31m

Dec 31 2023US$8mUS$764k

US$15m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$5mUS$737k

-US$50m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$7mUS$715k

-US$43m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$4mUS$199k

-US$23m

Compensation vs Market: Nikhil's total compensation ($USD8.08M) is above average for companies of similar size in the German market ($USD1.44M).

Compensation vs Earnings: Nikhil's compensation has been consistent with company performance over the past year.


CEO

Nikhil Lalwani (46 yo)

4.2yrs

Tenure

US$8,078,353

Compensation

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...


Leadership Team

NamePositionTenureCompensationOwnership
Nikhil Lalwani
President4.2yrsUS$8.08m1.92%
€ 20.1m
Stephen Carey
Senior VP of Finance & CFO8.5yrsUS$2.58m0.83%
€ 8.7m
Chad Gassert
Senior Vice President of Corporate Development & Strategy3yrsUS$1.90m1.24%
€ 13.0m
Christopher Mutz
Senior Vp & Head of Rare Disease3.8yrsUS$1.91m0.43%
€ 4.5m
Ori Gutwerg
Senior Vice President of Generics3.8yrsUS$1.94m0.40%
€ 4.1m
Muthusamy Shanmugam
Head of R&D3yrsno data0.26%
€ 2.7m
James Marken
Senior Vice President of Operations8.5yrsUS$1.43m0.60%
€ 6.3m
Elizabeth Powell
Chief Compliance Officer & Head of Legal of Rare Disease2.8yrsno datano data
Meredith Cook
Senior VP2.3yrsno data0.29%
€ 3.0m
Krista Davis
Senior VP & Chief Human Resources Officer2.2yrsno data0.26%
€ 2.7m
Mary Pao
Chief Medical Officer2.8yrsno datano data
Thomas Rowland
Senior VP & Head of Established Brands3yrsno data0.17%
€ 1.8m

3.0yrs

Average Tenure

51.5yo

Average Age

Experienced Management: BSFA's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Nikhil Lalwani
President4.2yrsUS$8.08m1.92%
€ 20.1m
Muthusamy Shanmugam
Head of R&D3yrsno data0.26%
€ 2.7m
Patrick Walsh
Independent Chairman6.5yrsUS$422.21k0.38%
€ 4.0m
Antonio Pera
Independent Director4.3yrsUS$393.25k0.16%
€ 1.7m
Thomas Haughey
Independent Director6.5yrsUS$412.21k0.26%
€ 2.8m
Jeanne Thoma
Independent Director4.3yrsUS$395.75k0.21%
€ 2.2m
Renee Tannenbaum
Independent Director2.7yrsUS$392.37k0.12%
€ 1.2m
Matthew Leonard
Independent Director1.3yrsUS$470.76k0.061%
€ 644.0k

4.2yrs

Average Tenure

61.5yo

Average Age

Experienced Board: BSFA's board of directors are considered experienced (4.2 years average tenure).